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Cyanine 5.5 Conjugated Nanobubbles as a Tumor
Selective Contrast Agent for Dual UltrasoundFluorescence Imaging in a Mouse Model
Liyi Mai1., Anna Yao1., Jing Li2, Qiong Wei1, Ming Yuchi2, Xiaoling He3, Mingyue Ding2, Qibing Zhou1,4*
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Geoscience, Wuhan, Hubei, China, 4 Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, United States of America

Abstract
Nanobubbles and microbubbles are non-invasive ultrasound imaging contrast agents that may potentially enhance
diagnosis of tumors. However, to date, both nanobubbles and microbubbles display poor in vivo tumor-selectivity over
non-targeted organs such as liver. We report here cyanine 5.5 conjugated nanobubbles (cy5.5-nanobubbles) of
a biocompatible chitosan–vitamin C lipid system as a dual ultrasound-fluorescence contrast agent that achieved tumorselective imaging in a mouse tumor model. Cy5.5-nanobubble suspension contained single bubble spheres and clusters of
bubble spheres with the size ranging between 400–800 nm. In the in vivo mouse study, enhancement of ultrasound signals
at tumor site was found to persist over 2 h while tumor-selective fluorescence emission was persistently observed over 24 h
with intravenous injection of cy5.5-nanobubbles. In vitro cell study indicated that cy5.5-flurescence dye was able to
accumulate in cancer cells due to the unique conjugated nanobubble structure. Further in vivo fluorescence study
suggested that cy5.5-nanobubbles were mainly located at tumor site and in the bladder of mice. Subsequent analysis
confirmed that accumulation of high fluorescence was present at the intact subcutaneous tumor site and in isolated tumor
tissue but not in liver tissue post intravenous injection of cy5.5-nanobubbles. All these results led to the conclusion that
cy5.5-nanobubbles with unique crosslinked chitosan–vitamin C lipid system have achieved tumor-selective imaging in vivo.
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achieve the tumor selectivity is to use specific ligand-conjugated
bubbles such as cyclic RGD peptides targeting tumor angiogenesis
[13–15]. Nevertheless, the complex vascular structure and
multiple growth markers of tumors at different stages pose
a significant challenge to the effectiveness of this tumor-selective
delivery strategy [16,17]. Park and coworkers recently suggested
that for any nano-drug delivery system, the tumor selective
delivery over non-targeted organs must be first demonstrated
in vivo, rather than on the assumption of the EPR effects by the
size of nanoparticles [18]. The non-specific distribution of
reported lipid nanobubbles may be attributed to the chemical
composition of shell materials used, mostly neutral lipids and
polyethylene glycol modified derivatives [7–11]. Thus, we
hypothesized that using a negatively charged lipid as the major
shell component such as ascorbyl palmitate could potentially
change the in vivo distribution profile of nanobubbles.
Dual functional contrast agent has a potential to further
enhance the diagnosis of tumor [19,20], especially with fluorescence imaging that has been used in the application of imageguided resection of tumors to increase overall survival [21–23].
Fluorescence bubbles have been reported with quantum dots,
chemical dyes using tumor-specific ligands such as folate or

Introduction
Nanobubbles and microbubbles as soft shell spheres containing
inert gases such as perfluorocarbons or sulfur hexafluoride are
contrast agents developed for non-invasive ultrasound imaging [1–
3]. The enhanced ultrasound imaging signals have been attributed
to the elastic compression and expansion of bubbles upon
irradiation, resulting in modulation of reflected sound waves [1–
3]. Nanobubbles and microbubbles have recently been investigated in the diagnosis and prognosis of tumors to reveal tumor
vascular structures [4–6]. Compared to microbubbles, lipid
nanobubbles with size below 500 nm have been reported to
produce better ultrasound imaging enhancement [7–11] due to
the enhanced permeation and retention (EPR) effects at tumor
vascular leaks with pore size up to 780 nm [12]. However, to date,
both nanobubbles and microbubbles display poor in vivo tumorselectivity and have a short life of 30 min or less in vivo after being
intravenously delivered [7–11]. For example, in addition to tumor
imaging, phospholipid nanobubbles recently reported by Yin and
coworkers produced extensive and strong ultrasound imaging
enhancement in normal kidney and liver tissues in vivo, indicating
poor tumor selectivity even with EPR effects [11]. One strategy to
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Science & Technology Co. Ltd., China), ascorbyl palmitate
(220 mg), 1,2-hexadecandiol (6 mg) in sterile phosphate buffer
saline solution (PBS, pH 7.4, 58 mL) were added solutions of
tween-60 in PBS (3% w/w, 2 mL) and then 1 N NaOH (300 mL).
The resulting mixture was cooled down to 10uC in an ice bath and
degassed for 10 min with 0.2 mM filtered perfluoropropane gas
(C3F8, 99.7%, Institute of Physical and Chemical Engineering in
Nuclear Industry & Huahei Technology Development Co., Ltd.,
China). For the sonication process, the tip of ultrasound horn was
lowered approximately 2 mm below the surface of the solution to
ensure effective mixing of particles and gas. The suspension was
sonicated under C3F8 gas at 540 W for 80 cycles with working and
resting time of 5 and 10 s per cycle, respectively. The temperature
of the solution was maintained below 15uC with an ice bath
throughout the entire sonication process. A chitosan solution (low
molecular weight, 0.5% w/w in 0.5% acetic acid aqueous solution,
150 mL) was then slowly added to the mixture under sonication at
36 W. The suspension was sonicated again at 36 W for 40 cycles
with working and resting time of 5 and 10 s per cycle, respectively.
The resulting milky solution (,50 mL) was centrifuged at 2506g
for 45 min at 4uC in a 50 mL conical tube. The middle section of
obtained supernatant was slowly drained to vials and sealed under
C3F8 (approximately 30 mL). Cy5.5-nanobubble suspension
(5 mL each) were obtained by adding cy5.5 N-hydroxysuccinimide
ester in DMSO (20 mg/mL, 0.6 mL, GE Health, USA) and then
a crosslinker bis(succinimidyl) penta(ethylene glycol) (BS(PEG)5,
Thermo Scientific, USA) in DMSO (1.5 mg/mL, 10 mL) after
12 h. The pH of the final Cy5.5-nanobubble suspension was
measured as 7.2. To determine the percentage of conjugated cy5.5
on nanobubbles, cy5.5-nanobubble suspension (1 mL each63) was
centrifuged at 10,000 g610 min, the UV absorbance of free
cy5.5 in the supernatant was measured at 688 nm as compared to
a standard curve. The percentage of conjugation was calculated as
41% based on the molar ratio of free cy5.5 detected in supernatant
over the total activated ester of cy5.5 added.
As a control solution for cy5.5-nanobubbles, cy5.5 free acid plus
nanobubble mixture (cy5.5+nanobubbles) was obtained by first
synthesis of nanobubble suspension (5 mL each) without the
addition of cy5.5 N-hydroxysuccinimide ester as described above.
Cy5.5 free acid (20 mg/mL in DMSO, 0.6 mL, GE Health, USA)
was then added in 5 mL nanobubble suspension. Another control
solution for cy5.5-nanobubbles was the cy5.5 conjugated chitosan
solution (cy5.5-chitosan) as the shell material without nanobubble
structure. Cy5.5-chitosan solution was generated by adding low
molecular chitosan solution (0.5% w/w in 0.5% acetic acid
aqueous solution, 12.5 mL) in PBS solution (5 mL) containing 2%
hydroxyethyl starch (200/0.5) followed by addition of cy5.5 Nhydroxysuccinimide ester (20 mg/mL in DMSO, 0.6 mL) and

antibody [24–28]. However, most of them focused on the in vitro
cell labeling while no effective in vivo tumor selectivity has been
demonstrated. More recently, nanobubble lipid shells are found to
have potential toxic effects on kidney and liver and interfere with
immune responses [29,30]. There is also safety concern of excess
perfluorocarbon gas in the blood due to its low dissolving rate [3].
Thus, tumor-selective delivery is highly desirable to prevent the
potential toxic issues of excess nanobubbles in circulation.
We report here a biocompatible chitosan-vitamin C lipid
nanobubble system, cyanine 5.5-conjugated nanobubbles (cy5.5nanobubbles) as a dual ultrasound–fluorescence contrast agent
that achieved tumor-selective imaging in vivo. Fluorescence cy5.5
has maximum excitation and emission in the near infrared region
at 675 and 690 nm, respectively and is commonly used in in vivo
optical imaging due to low background interference. Cy5.5nanobubbles were synthesized by sonication method with fully
characterized physical properties. The enhancement of ultrasound
and fluorescence signals at the tumor site was assessed in vivo post
intravenous injection of cy5.5-nanobubbles. In vitro study of
cellular uptake of cy5.5 was also investigated in cancer cells with
nanobubbles. Finally, tumor selective imaging over non-targeted
organ was assessed by both in vivo and tissue studies of the tumor
mouse model post cy5.5-nanobubble injection.

Materials and Methods
Ethics Statement
The animal protocol was approved by the Animal Care and Use
Committee of College of Life Science and Technology at
Huazhong University of Science and Technology.

Materials
All chemicals were purchased from Sigma-Aldrich (USA), J&K
Scientific Ltd. (China) or Sinopharm Chemical Reagent Co., Ltd
(China) unless otherwise specified. Murine liver cancer cells H22
were from Shanghai Institute of Life Science Cell Culture Center
(China), and human liver cancer cell line Hep3B was obtained
from ATCC (USA). Cells were maintained in RPMI-1640 or high
glucose DMEM medium (Invitrogen, USA) supplemented with
10% heat-inactivated fetal bovine serum (FBS), 25 mM HEPES,
2 mM L-glutamine, 0.1 mM nonessential amino acids, 1.0 mM
sodium pyruvate, 50 U/mL penicillin and 50 mg/mL streptomycin at 37uC and 5% CO2.

Synthesis of cy5.5-nanobubbles
Ultrasound generation of nanobubbles was carried out on
a JY99-II DN ultrasound homogenizer with a Ø20 mm horn
(Ningbo Scientz Biotechnology Co. Ltd, China). To a suspension
of hydroxyethyl starch (200/0.5, 1.20 g, Wuhan HUST Life

Figure 1. Stepwise synthesis of cy5.5-nanobubble suspension.
doi:10.1371/journal.pone.0061224.g001
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Figure 2. Physical properties of cy5.5-nanobubbles. a) microscopic images of cy5.5-nanobubbles in a 50 mm grid square of a hemocytometer
under 1006 objective lens with A, B and C as expanded views of selected areas in the left panel; b) microscopic images of cy5.5-nanobubbles on
a hemocytometer under phase light (left panel) or with cy5.5 emission filter (right panel); c) hydrodynamic sizes of cy5.5-nanobubbles as obtained by
dynamic light scatting measurement in PBS solution; d) schematic illustration of the setup for analysis of ultrasound imaging property of
nanobubbles; e) ultrasound images of nanobubbles at 5 and 12 MHz.
doi:10.1371/journal.pone.0061224.g002

then BS(PEG)5 crosslinker (1.5 mg/mL in DMSO, 10 mL) as
described above.

solution inside the latex finger at the bottom, and ultrasound
images were captured at room temperature.

Characterization of cy5.5-nanobubbles

In vitro Cellular Fluorescence Study

Microscopic imaging analysis was carried out on a Nikon
Eclipse 80i microscope equipped with a Plan Apochromat VC
1006 oil objective lens (Nikon Instrument, Japan). Cy5.5nanobubble suspension (50 mL) was diluted with PBS solution
(100 mL) and loaded onto a hemocytometer with cover slides. The
field of view was first adjusted to the center of hemocytometer that
has gridded squares of a size of 50 mm under a 406objective lens.
Images and videos of nanobubbles were then recorded under the
1006 oil objective lens with Nikon NIS-Elements BR imaging
capturing software. The scale of the field of view was calibrated
with the average size of gridded squares. Microscopic cy5.5
fluorescence image of nanobubbles was recorded similarly with
IX71 Inverted Microscope (Olympus Corporation, Japan)
equipped with a digital camera.
The hydrodynamic size measurement of nanobubbles was
carried out with a Nano-ZS90 particle analyzer (Malvern, United
Kingdom). Nanobubble suspension (200 mL) was mixed in PBS
solution (1.25 mL), and the hydrodynamic size and zeta potential
were recorded after equilibration at 37uC for 5 min. The
excitation and emission spectra of cy5.5-nanobubble suspension
were obtained in PBS solution (200 mL in 2 mL) using Hitachi F4500 fluorescence spectrometer (Tokyo, Japan) at room temperature (Figure S1-a).

Hep3B cells (20,000 per well) were seeded in the growth media
(400 mL) on a 48-well plate overnight. A solution of cy5.5+nanobubbles, cy5.5-chitosan or cy5.5-nanobubbles (10 mL each) was
then added to each well and mixed gently with cell media. After
incubation for 3 h at 37uC, cell media were removed and cells
were washed once with PBS. Images of each treatment under
phase light and with cy5.5 fluorescence emission were captured
with IX71 Inverted Microscope equipped with a digital camera.

Mouse Tumor Model
SFP nude female BALB/c mice (approximately 20 g) were
obtained from Hunan Slake Jingda Experimental Animal Co.
Ltd., China. Murine liver cancer cells H22 were grown in the
BALB/c mice intraperitoneally. Mice were euthanized after 6 days
and H22 cells were harvested with PBS solution. H22 cells were
washed once with sterile PBS and were injected subcutaneously
(36106 cells per mouse) at the lower back of nude BALB/c mice
[31]. Typically, tumors reached an average size of 0.860.6 cm
after 7 days post injection, and mice were used in the following
imaging analyses.

In vivo Ultrasound and Fluorescence Imaging
For ultrasound imaging of subcutaneous tumors, mice were
restrained on a flat platform without anesthetics. Ultrasound
transducer was first positioned gently on the top of tumors parallel
to the direction of spinal cord and then at an orthogonal angle.
Ultrasound images were recorded on a LOGIQ 7 Ultrasound
System with a thyroid transducer at a frequency of 12 MHz prior
and post a single intravenous injection of cy5.5-nanobubble
suspension (4 mL per gram of body weight) through the tail vein.
Mice were then released and allowed to rest in the intervals
between time points of 10, 30, 60, 120 and 240 min post injection.
A total of 4 mice were used for in the ultrasound study.

Ultrasound Imaging Property of cy5.5-nanobubbles
The setup for analysis of ultrasound reflection by cy5.5nanobubbles included a latex glove fingertip containing 10 mL
PBS solution in a water bath with ultrasound transducer on one
side. Ultrasound images were recorded on a LOGIQ 7 Ultrasound
System (GE Healthcare, USA) in B flow mode with a thyroid
transducer. Solutions in the latex finger and water bath were first
verified to be free of bubbles by ultrasound imaging. Cy5.5nanobubble suspension (150 mL) was then injected into the PBS

Figure 3. In vivo ultrasound images of subcutaneous tumors with injection of cy5.5-nanobubble suspension. Ultrasound images were
obtained with LOGIQ7 system with a thyroid transducer at 12 MHz. The location of subcutaneous tumor was marked with red circle in the left panel.
Top and bottom panels are images of the same tumor at orthogonal angles. The basal periphery of tumor was indicated with arrows in images.
Images are representative of 4 mice investigated.
doi:10.1371/journal.pone.0061224.g003
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Figure 4. In vivo fluorescence images of mouse tumors model with cy5.5 solutions. Mice with average tumor sizes of 0.860.6 cm (marked
with red circles with arrows in left panels) were injected intravenously with: a) cy5.5 free acid+nanobubbles; b) cy5.5-choitosan solution as a control of
shell materials without nanobubble structure; and c) cy5.5-nanobubble suspension. For panels b and c, cy5.5 fluorescence emission is shown under
the same scale of radiation efficiency for comparison of intensity at the tumor sites. Fluorescence images are shown as overlaid fluorescence emission
profiles on photographic images.
doi:10.1371/journal.pone.0061224.g004

sion (4 mL per gram of body weight) through the tail vein (3 mice
per group). Images were captured with IVISH Lumina XR
Imaging System (Caliper Life Sciences, USA) using a set of
imaging sequence including photograph and fluorescence modes
with excitation wavelengths at 640 nm and cy5.5 emission filter.
Fluorescent images in radiation efficiency were processed with
Living ImageH software according to manufacturer’s recommendation. Briefly, cy5.5 fluorescence emission image of mice was

For the in vivo fluorescence imaging analysis, the optimal
excitation wavelength for cy5.5 emission in nude mice was first
assessed to be 640 nm on a naı̈ve mouse with subcutaneous
injection of 100 mL cy5.5-nanobubble suspension. During the
fluorescence imaging, mice were under gas anesthesia with oxygen
and isoflurane (Hebei Jiupai Pharmaceuticals, China). Images
were obtained prior and post a single intravenous injection of
cy5.5+nanobubble, cy5.5-chitosan or cy5.5-nanobubble suspen-

Figure 5. Persistent tumor-selective imaging with cy5.5-nanobubbles. a) Folds of in vivo fluorescence intensity enhancement at tumor site
over 24 h; and b) fluorescence image of the mouse tumor site at 24 h post injection.
doi:10.1371/journal.pone.0061224.g005
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Figure 6. In vitro cellular uptake study of cy5.5-nanobubbles. Images of cellular accumulation of cy5.5 fluorescence in liver cancer Hep3B
cells upon treatment of a) cy5.5 free acid+nanobubbles; b) cy5.5-chitosan solution; or c) cy5.5-nanobubbles for 3 h at 37uC. Top and bottom panels
are images obtained under phase light and with cy5.5 emission filter, respectively.
doi:10.1371/journal.pone.0061224.g006

chitosan was also crosslinked to enhance such stabilization through
amide bond formation. Finally, addition of water soluble
hydroxylethyl starch (200/0.5), a major constituent of blood
substitutes used in clinic, provided a highly branched polymeric
structure to reduce potential cluster formation of nanobubbles via
hydrogen bonds with chitosan shell. Thus, optimized synthesis of
stable cy5.5-nanobubbles was achieved and summarized in
Figure 1. Briefly, nanobubbles were generated with 1,2-hexadecandiol in the presence of hydroxylethyl starch in PBS solution.
Chitosan was added prior to the second round sonication while
crosslinker BS(PEG)5 was added to nanobubble suspension at 0.25
equivalent to the glucosamine unit of chitosan. Incorporation of
fluorescence cyanine 5.5 (cy5.5) on nanobubbles was carried out
before the crosslink process. The resulting cy5.5-nanobubble
suspension was found to be stable over 6 weeks at 4uC.

obtained with spectral unmixing method to remove background
emission that was obtained at excitation at 535, 570, or 605 nm.
Folds of fluorescence increase at tumor sites over time were
calculated by the ratio of total radiation efficiency over a uniformly
defined area pre- and post-injection with Living ImageH software.
For fluorescence imaging of isolated tumors and tissues, mice
were euthanized after 24 h post intravenous injection of cy5.5nanobubble or PBS solution. The skin containing tumor was
exposed for imaging. The tumor and liver tissues were then
isolated and fluorescence images were obtained and processed
similarly as described above.

Results and Discussion
Synthesis of cy5.5-nanobubbles
Ascorbyl palmitate was chosen as a major component for the
new formulation of nanobubbles due to the facts that it is a highly
biocompatible vitamin C lipid and has a negative charge at
physiological pH that can stabilize bubbles via ionic interactions.
The generation of nanobubbles was initially carried out by
sonication of a solution of 0.37% ascorbyl palmitate in phosphate
buffer saline solution (PBS) under perfluoropropane gas with only
0.1% tween-60 that was able to help the formation and
stabilization of nanobubbles. Nanoscale bubbles were found only
with two rounds of sonification at power of 540 W and then 36 W
as indicated by dynamic light scattering analysis (DLS). However,
the resulting nanobubble suspension was not stable over a period
of 24 h at 4uC with precipitations.
Stabilization of nanobubbles was achieved by first adding
a dihydroxylated lipid that markedly reduced precipitations in
nanobubble suspension possibly via enhanced hydrophobic interaction in the lipid layer. Secondly, chitosan is a polymer of
glucosamines containing amino groups with average pKa of 6.5
and are positively charged under neutral pH. Addition of chitosan
at pH 7 stabilized nanobubbles via ionic interaction with the
negative charged ascorbate surface of nanobubbles. In addition,
PLOS ONE | www.plosone.org

Characterization of cy5.5-nanobubbles
Sizes of nanobubbles were first confirmed by microscopic
analysis with both static and video imaging. Static microscopic
imaging analysis has been applied successfully to determine size,
structure and density of microbubbles but not for sub-microscale
bubbles [32]. We found that with the use of an oil-immersed 1006
objective lens, the resolution of microscopic imaging analysis could
be extended to 0.07 mm/pixel that was sufficient for analysis of
particle sizes above 300 nm. Microscopic images of nanobubbles
in a 50 mm grid square of a hemocytometer under the 1006
objective lens are shown in Figure 2a. Diameters of nanobubbles
were estimated from the average number of pixels along two
orthogonal axes. Three types of particles were observed including
grey solid spheres, white hollow circles and clusters of beads.
Expansion of selected areas in the left panel (Figure 2a-A)
indicated that grey spheres and white hollow circles were particles
around 400 and 800 nm, respectively while clusters were typically
groups of hallow circles (Figure 2a-B and C). Microscopic analysis
of recorded video of nanobubbles under the 1006 objective lens
(Video S1) revealed that all particles were in constant vibrational
6
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Figure 7. Selective accumulation of cy5.5-nanobubbles at mouse tumor site. a) In vivo fluorescence images of the front side of mouse at 4
and 24 h post injection revealing that bladder is the alternative location of cy5.5-nanobubbles (tumor is located at the backside); b) photograph and
the cy5.5 fluorescence image of an intact subcutaneous tumor at 24 h post intravenous injection; c) comparison of cy5.5 fluorescence in isolated liver
and tumor tissues of the same mouse at 24 h post intravenous injection; d) comparison of cy5.5 fluorescence in isolated tumor tissues with cy5.5nanobubbles (A) or plain PBS injection (B) at 24 h post intravenous injection. Fluorescence images are shown as overlaid fluorescence emission
profiles on photographic images.
doi:10.1371/journal.pone.0061224.g007

scattering through the bubble structure. In addition, cluster of
beads were indeed linked spheres that vibrated together.
Therefore, microscopic imaging analysis at high magnification
confirmed that synthesized nanobubbles were spherical bubbles
and clusters of these bubbles with the size ranging between 400–
800 nm. The cluster formation of bubbles was found as the result

motion in and out of the field of view, which made the estimation
of the particle density of the solution infeasible. More importantly,
a single bubble could be observed either as a grey solid sphere
when it moved away from the focus of the field or as a white
hollow circle when it moved toward focus of the field. Thus, the
hollow white circle may be the result of self-magnification by light
PLOS ONE | www.plosone.org
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tumor was established in nude mice at lower back with an average
size of 0.860.6 cm. The ultrasound images of tumor were
obtained at two orthogonal angles prior injection of cy5.5nanobubble suspension as indicated in Figure 3. Under ultrasound, the subcutaneous tumor appeared as an irregular hill shape
with the skin as the top bright contour and tumor as a dark
hypoechoic area. In general, an irregular hypoechoic dark area
with fully enclosed periphery in two orthogonal ultrasound images
is indicative of a malignant tumor in B mode [36,37]. However,
the basal periphery of tumor was poorly defined in the top panel of
ultrasound image as compared that in the bottom panel (indicated
with arrows in Figure 3), and thus requiring additional tests to
confirm the presence of a malignant tumor.
Following an intravenous injection of cy5.5-nanobubble suspension in mice, ultrasound images of tumor were recorded over
a period of 4 hours (Figure 3). While the tumor remained as
a hyposonically dark area, the basal periphery of tumor became
highly visible with strong ultrasound signals as a white line at both
orthogonal angles at 30 min post injection (indicated with arrows
in Figure 3). These results led to a consistent indication of the
presence of a malignant tumor, suggesting that nanobubbles were
able to enhance the diagnosis of subcutaneous tumor as a contrast
agent. In addition, the enhancement of tumor basal periphery
persisted strongly for 2 hours and then gradually decreased within
next 2 hours. At 4 h post intravenous injection, the ultrasound
images of tumor were found to be similar to those of prior injection
(Figure 3). The loss of the ultrasound enhancement at 4 h
suggested the absence of cy5.5-nanobubbles at the periphery of
tumor site, possibly due to the rupture of nanobubbles in vivo as
that of reported nanobubbles [7–11]. This result, on the other
hand, confirmed that the increased contrast of tumor base
periphery at early time points was a result of accumulation of
cy5.5-nanobubbles at tumor site over a time of 4 h, much longer
than that of reported lipid nanobubbles [7–11]. The penetration of
cy5.5-nanobubbles into tumor stroma was not observed in the
ultrasound imaging, which may be due to the relative large sizes of
cy5.5-nanobubbles and possibly that the available ultrasound
imaging mode was not optimized for cy5.5-nanobubbles. More
importantly, in contrast to reported lipid nanobubbles, no
significant enhancement by cy5.5-nanobubbles in the normal rat
liver tissue was observed in vivo in ultrasound imaging (Figure S1c), suggesting that cy5.5-nanobubbles was able to selectively
accumulate in the periphery of tumor site over non-targeted
organs such as liver. During and post the imaging process, no
abnormal mouse behavior or mortality was observed after the
injection of nanobubble suspension, suggesting the safety of cy5.5nanobubbles via intravenous delivery.
The in vivo fluorescence images of the mouse prior and post
intravenous injection of controls and cy5.5-nanobubbles are
shown in Figure 4. Intravenous injection of free cy5.5+nanobubbles led to a general fluorescence signal at the back of the mouse
after 30 min, which gradually disappeared over time post injection
(Figure 4a). No significant fluorescence was detected at tumor site
with cy5.5+nanobubble control. Additional fluorescence imaging
analysis revealed that there was a high fluorescence signal in the
mouse bladder at 2 h post injection of free cy5.5+nanobubbles,
which was significantly decreased after 24 h (Figure S1-d). Our
results suggested that free cy5.5 was likely removed by renal
filtration from the blood circulation and excreted via mouse
bladder. Injection of the cy5.5-chitosan control of shell material
without nanobubble structures resulted in a weak cy5.5 emission at
the tumor site (Figure 4b). The fluorescence intensity then
decreased significantly at 6 h. In stark contrast, accumulation of
red fluorescent emission was observed at the tumor site as early as

of addition of chitosan solution following by the crosslink agent,
possibly due to the covalent linkage of multiple single bubbles. The
incorporation of cy5.5 on nanobubbles was then verified with
microscopic imaging method. The image obtained under phase
light matched closely with the red fluorescence color located on
the bubbles in the image captured with cy5.5 emission filter
(Figure 2b). In contrast, the control of cy5.5+nanobubbles only
resulted in a blur red fluorescent background. This result suggested
that cy5.5 dye was covalently attached to the surface of
nanobubbles.
Hydrodynamic sizes of cy5.5-nanobubbles were determined
with dynamic light scattering analysis as a complementary method
to microscopic analysis (Figure 2c). The zeta average size was
359.3 nm in PBS solution at 37uC in the range between 200–
800 nm with a polydispersity distribution of particle sizes (PDI) at
0.46. Nanobubbles were found to have a negatively charged
surface with zeta potential of 219.17 mV. The formation of
nanobubble clusters may be responsible for the relative high
polydispersity index of nanobubble suspension as a polydispersed
system. Further separation of nanobubble suspension with
centrifugation did not result in significant removal of these
nanobubble clusters. Therefore, the above synthesized nanobubble
suspension was used in the following physical and biological
analyses. In addition, the count rate was found to remain
approximately at 1616103 particles per second during the DLS
measurement with a 6.25-fold diluted sample, and thus was used
as an index to represent the nanobubble density of the synthesized
suspension as 1.016106 bubbles per second. Additional characterization of nanobubbles with transmission electron microscopic
analysis was not successful because synthesized cy5.5-nanobubbles
were ruptured under experimental condition used. As a comparison, the cy5.5 free acid plus nanobubbles control has a zeta
average hydrodynamic size of 382.4 nm with a PDI of 0.50 (Figure
S1-b), indicating that covalent conjugation of cy5.5 on the
nanobubbles did not significantly increase the sizes of nanobubbles.
The enhanced reflection of ultrasound by cy5.5-nanobubbles in
ultrasound imaging was first assessed in a latex finger as shown
schematically in Figure 2d. Ultrasound imaging upon injection of
nanobubble suspension was evaluated at a frequency of 5 or
12 MHz with the same setting of instrumental parameters
(Figure 2e). Cy5.5-anobubbles produced a strong ultrasound
signal as bright white spots in both images as compared to the
low signal dark background. On the other hand, the enhanced
ultrasound signal at a frequency of 12 MHz was much brighter
than that at 5 MHz under the same condition. The enhancement
of ultrasound signal by bubbles correlates to their harmonic
frequency, which generally follows Rayleigh-Plesset-like equation
and depends on the shell material, inner and outside diameters
and interaction with the media [33–35]. Thus, the enhanced
contrast by cy5.5-nanobubbles at a high frequency may reflect
a unique elasticity due to the crosslinked chitosan-lipid ascorbate
shell structure. This unique elasticity of cy5.5-nanbubbles may also
explain why the ultrasound image with cy5.5-nanbubbles in the B
mode had a slightly better contrast than that in the inverted phase
harmonic mode, the latter of which is commonly used for
micrcobubbles. Therefore, the synthesized nanobubbles were able
to enhance ultrasound signals in ultrasound imaging. Based on
these results, the following in vivo ultrasound imaging studies were
carried in the B-flow mode at the frequency of 12 MHz.

Tumor Selective Imaging with cy5.5-nanobubbles
Cy5.5-nanobubbles as a dual ultrasound-fluorescence contrast
agent were then assessed in a mouse tumor model. Subcutaneous
PLOS ONE | www.plosone.org
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30 min post injection of cy5.5-nanobubbles and reached a maximum at 4 h. The increase of the fluorescence at tumor site
concurred with the decrease of fluorescence emission of mouse
ears where blood vessels are close to surface, suggesting
accumulation of cy5.5-nanobubbles at tumor site and a decreased
level in bloodstream. These results indicated that tumor selective
cy5.5 fluorescence imaging could be only effectively achieved with
covalently conjugated cy5.5-nanobubbles not with the mixture of
free cy5.5+nanobubbles, and also that the nanobubble structure
was critical for the tumor selective imaging.
The accumulated cy5.5 fluorescence at tumor site with cy5.5nanobubbles was consistent with the tumor selective ultrasound
imaging in Figure 3. Interestingly, the highest intensity of cy5.5
fluorescence concurred with the disappearance of enhancement in
the ultrasound imaging at 4 h post intravenous injection,
suggesting that cy5.5-nanobubble shell material remained at the
tumor site even though cy5.5-nanobubbles were ruptured. Thus,
cy5.5-nanobubbles were an effective dual contrast agent for
selective imaging of tumor in vivo. The fluorescence accumulation
profile of the tumor site over a period of 24 h in vivo was
summarized in Figure 5a. The fluorescence intensity of the tumor
site reached approximately 6 folds of that prior injection in 4 hours
and remained persistently high even after 24 h (Figure 5b).
In vitro study of cy5.5 cellular uptake was then investigated
whether cy5.5-nanobubbles were able to accumulate selectively in
tumor cells. Cell images under phase light and with cy5.5 emission
filter are shown in Figure 6 after liver cancer Hep3B cells treated
with cy5.5-nanobubble suspension or controls for 3 h. A low level
of cy5.5 fluorescence emission signal was observed inside cells
when treated with cy5.5-nanobubble suspension. In contrast,
neither cy5.5+nanobubble nor cy5.5-chitosan control produced
any red fluorescence inside cells. This result indicated that cy5.5nanobubbles were able to enter in cells, which might explain why
the red fluorescence accumulated selectively at tumor site in vivo.
In addition, this cellular uptake result also suggested that cy5.5chitosan as a shell material without nanobubble structures might
not be adsorbed to tumor tissue in vivo. Taken together, these
results suggested that only the cy5.5 conjugated crosslinked
chitosan-lipid vitamin C nanobubbles could achieve tumorselective imaging in vivo in contrast to other lipid or phospholipid
nanobubbles [7–11].
The tumor-selective targeting by cy5.5-nanobubbles was then
verified with both in vivo and collected tissue studies. Alternative
location of cy5.5-nanobubbles was observed in the bladder from
the front side of mouse at 4 h post injection (Figure 7, tumor is
located at the backside) while no significant fluorescent emission
was observed at the location of liver. The fluorescence intensity at
bladder decreased significantly after 24 h. The fluorescence signal
in the mouse bladder with cy5.5-nanobubbles might be due to the
released cy5.5 in the nanobubble suspension that was removed by
kidney as that of free cy5.5 control. The ratio of the fluorescence
emission in tumor versus bladder at 4 h was estimated approximately as 1:1.6 based on the area integration, indicating a quite
efficient selectivity of tumor site in vivo. In addition, high intensity
of cy5.5 fluorescence emission was found at the intact subcutaneous tumor underneath the skin at 24 h post intravenous
injection of cy5.5-nanobubbles as compared to the photography of
the tumor site (Figure 7b, left versus right panel). This result
confirmed that in vivo fluorescence images at tumor site at early
time points were indeed due to the presence of cy5.5-nanobubbles.
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Finally, there was dramatic higher emission intensity of cy5.5
fluorescence of isolated tumor tissues than that of liver tissues of
the same mouse, confirming that liver was not a major accumulation organ for cy5.5-nanobubbles (Figure 7c). Moreover, the
collected tumor tissue with cy5.5-nanobubble injection showed
a marked 28-fold increase of total fluorescence intensity versus that
with PBS injection (Figure 7d). All these results confirmed that
cy5.5-nanobubbles were able to achieve tumor-selective targeting
in vivo.
In conclusion, we present in this report cy5.5-nanobubbles as
a dual ultrasound-fluorescence contrast agent for selective tumor
imaging in vivo. Based on the results from the ultrasound and
fluorescence imaging analyses, it is suggested that the tumor
selectivity by cy5.5-nanobubbles could be attributed to the unique
crosslinked chitosan-ascorbyl palmitate structure with a negatively
charged surface. As shown by ultrasound imaging analysis
(Figure 3), cy5.5-nanobubbles accumulated at the tumor site
through the blood circulation in the initial 2 h post intravenous
injection, and then degraded over next 2 h. Meanwhile, the
fluorescence signal of cy5.5 conjugated shell materials could
remain at tumor site over 24 h (Figures 4c, 5 and 7b–d). In
contrast, free cy5.5 was quickly removed by renal filtration
followed by excretion via bladder (Figures 4a and S1-d). The indepth mechanisms of selective accumulation of cy5.5-nanobubbles
at tumor tissue are currently under investigation. Future direction
will be the investigation on whether the tumor selective imaging
can be further enhanced when a tumor-targeting ligand or
antibody is incorporated on the synthesized cy5.5-nanobubbles.

Supporting Information
Figure S1 a) Fluorescence excitation and emission spectra of
cy5.5-nanobubble suspension; b) hydrodynamic sizes of cy5.5 free
acid+nanobubble suspension as obtained by dynamic light scatting
measurement in PBS solution at 37uC; c) in vivo ultrasound
images of the normal liver of a Sprague-Dawley rat pre- and postiv injection of 200 mL of cy5.5-nanobubble suspension. Ultrasound images were obtained with LOGIQ7 system with a thyroid
transducer at 12 MHz. The image post injection was obtained at
2 min and no significant enhancement of ultrasound signal was
found afterwards; d) in vivo fluorescence images of the front side of
mouse at 2 and 24 h post injection of free cy5.5+nanobubbles,
confirming that cy5.5 was removed through renal filtration.
(TIF)
Video S1 A video clip of microscopic analysis of cy5.5nanobubbles on a hemocytometer under a Plan Apochromat
VC 1006 oil objective lens with a Nikon Eclipse 80i microscope.
(WMV)
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